A detailed history of Coppell Advisory Solutions LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Coppell Advisory Solutions LLC holds 190 shares of NBIX stock, worth $21,861. This represents 0.0% of its overall portfolio holdings.

Number of Shares
190
Previous 206 7.77%
Holding current value
$21,861
Previous $27.1 Million 3.63%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$130.86 - $143.19 $2,093 - $2,291
-16 Reduced 7.77%
190 $26.2 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $23,017 - $28,808
-217 Reduced 51.3%
206 $27.1 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $39,770 - $49,533
423 New
423 $50.5 Million
Q1 2023

May 19, 2023

SELL
$94.11 - $123.02 $39,808 - $52,037
-423 Closed
0 $0
Q4 2022

May 19, 2023

BUY
$106.72 - $127.06 $45,142 - $53,746
423 New
423 $50.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Coppell Advisory Solutions LLC Portfolio

Follow Coppell Advisory Solutions LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coppell Advisory Solutions LLC, based on Form 13F filings with the SEC.

News

Stay updated on Coppell Advisory Solutions LLC with notifications on news.